EyeGate Pharma Studies Entire Yr 2020 Monetary Success and Delivers Enterprise Update

WALTHAM, Mass., March 25, 2021 (Globe NEWSWIRE) — EyeGate Prescribed drugs, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a scientific-stage company developing and commercializing goods for managing inflammatory and immune conditions with a concentrate on the eye and anxious procedure, currently announced economic results for the year finished December 31, 2020 and offered an update on latest company and operational things to do.

“We are exceptionally delighted by our 2020 development and our sizeable company enhancements that mark a new section of strategic development,” mentioned Franz Obermayr, Ph.D., Acting Main Government Officer of EyeGate. “The acquisition of Panoptes was a transformative celebration that will permit EyeGate to make important strides past ophthalmology and create a strong solution pipeline with PP-001, a de-risked, scientific-stage asset with broad therapeutic prospective across a assorted selection of ocular, autoimmune and neurological indications. We are poised for an fascinating calendar year ahead as we foresee the initiation of multiple clinical research in both of those ophthalmology and systemic diseases.”

2020 and Current Small business Highlights:

• Panoptes Pharma acquisition: In December, EyeGate obtained Panoptes Pharma (“Panoptes”), a privately held medical phase biotech enterprise targeted on acquiring a novel proprietary modest molecule for the cure of intense eye illnesses with a significant unmet health-related have to have.

• Pipeline updates: The acquisition remodeled EyeGate’s pipeline with the addition of PP-001, a medical-stage, future-technology, inhibitor of dihydroorotate dehydrogenase (“DHODH”) with a validated immune-modulating mechanism and possible most effective-in-class specificity and potency to avoid off-focus on side consequences and lessen basic safety challenges.

  • Initially-in-class in ophthalmology purposes – PP-001 is in development with two medical-stage ophthalmic formulations: (1) PaniJect, an intravitreal injection for inflammatory illnesses of the eye with a Section 1b/2a protection and efficacy review done in people with posterior uveitis, and (2) PaniDrop, an eye drop for conjunctivitis and dry eye disorder with a completed Stage 1 safety review in healthier volunteers.

  • Other administration routes are also in improvement and IND enabling studies are underway for situations outside the ocular house.

• Administration transition: In February, Franz Obermayr, Ph.D., Taking care of Director and previous CEO of Panoptes Pharma, was appointed as Acting Main Government Officer and transitioned from his function at EyeGate as EVP Scientific Development.

• Private placement: Completed a non-public placement in January 2021 for net proceeds of approximately $8. million with an affiliate of Armistice Money.

2020 Economic Evaluate:

Tale continues

EyeGate acknowledged profits of $.012 million for the 12 months finished December 31, 2020, as opposed to $2.686 million for the 12 months ended December 31, 2019. The income identified for the year ended December 31, 2020 relevant to the Panoptes acquisition and the accompanying profits generated from authorities funds from the date of its acquisition. The revenue recognized for the yr finished December 31, 2019 was a result of the termination of the license agreements with Bausch Health and fitness Businesses, Inc. and no even more revenue will be identified similar to these agreements.

Study and growth expenses have been $3.566 million for the calendar year finished December 31, 2020, in contrast to $5.389 million for the year ended December 31, 2019. The minimize of $1.823 million was thanks to reduce OBG medical things to do following the completion of the PRK pivotal analyze in 2019, as perfectly as a $.500 million adjustment recorded in 2019 to the present benefit of the Jade receive-out payment due upon Fda acceptance of OBG. These decreases had been partially offset by increases in OBG manufacturing and the expiration of a pay as you go settlement in 2020 with a research vendor.

Standard and administrative fees have been $4.659 million for the yr finished December 31, 2020, in contrast to $4.406 million for the year ended December 31, 2019. The raise of $.253 million was generally owing to acquisition-associated expenditures for Panoptes, partially offset by a reduce in staff-associated charges.

Other earnings, web was $.133 million for the yr finished December 31, 2020, in contrast to $.108 million for the yr finished December 31, 2019. The raise of $.025 million was mostly thanks to a obtain identified on the dissolution of EyeGate Pharma S.A.S. in 2020, partially offset by much less curiosity earned on the Company’s funds balances.

Earnings tax expense was $.012 million for the 12 months ended December 31, 2020, as opposed to $.095 million for the year finished December 31, 2019. Each the 2020 and 2019 tax expense ended up a outcome of an boost in the point out blended tax price, which was used to the deferred tax legal responsibility harmony.

Dollars and hard cash equivalents were $1.186 million as of December 31, 2020, compared to $3.777 million as of December 31, 2019. The minimize in dollars and dollars equivalents was principally owing to funds outflows to fund the Company’s operations and to get Panoptes, partly offset by dollars been given from a registered immediate featuring, financial loan cash under the Paycheck Defense Software, and warrant exercise routines.

About EyeGate

EyeGate is a scientific-phase pharmaceutical corporation building and commercializing products and solutions for managing inflammatory and immune disorders with a emphasis on the eye and nervous procedure. PP-001, EyeGate’s lead clinical-stage drug solution, is a upcoming-technology, non-steroidal, immuno-modulatory and little-molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with finest-in-course picomolar efficiency and a validated immune modulating mechanism designed to overcome the off-target facet outcomes and security difficulties associated with past technology DHODH inhibitors. PP-001 has been designed in two scientific-phase ophthalmic formulations PaniJect, an intravitreal injection for inflammatory health conditions of the eye including posterior uveitis, and PaniDrop, a novel nano provider technologies eye drop for ocular surface area ailments these as viral conjunctivitis and dry eye disease. Intravenous and oral formulations are also in growth for conditions outdoors the ocular place. In addition, EyeGate is establishing Ocular Bandage Gel (“OBG”), a modified type of the organic polymer hyaluronic acid, designed to shield the ocular floor to allow re-epithelialization of the cornea and enhance ocular area integrity. OBG, with distinctive qualities that help hydrate and safeguard the ocular area, is in clinical analysis for people undergoing photorefractive keratectomy (“PRK”) surgery for corneal wound restore immediately after refractive surgical procedure and patients with punctate epitheliopathies (“PE”) as a consequence of dry eye. For extra information and facts, please stop by www.EyeGatePharma.com.

Forward-Searching Statements

Some of the statements in this push release are “forward-looking” and are made pursuant to the risk-free harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements incorporate statements relating to, amid other things, the commercialization initiatives and other regulatory or internet marketing approval endeavours pertaining to EyeGate’s products and solutions, such as EyeGate’s PP-001 and OBG merchandise, as perfectly as the accomplishment thereof, with this kind of approvals or achievement could not be attained or reached on a well timed basis or at all. These statements contain risks and uncertainties that might bring about outcomes to vary materially from the statements set forth in this press launch, which include, between other issues, selected risk variables explained under the heading “Risk Factors” contained in EyeGate’s Once-a-year Report on Sort 10-K submitted with the SEC on March 25, 2021 or described in EyeGate’s other community filings. EyeGate’s final results may well also be afflicted by components of which EyeGate is not currently conscious. The ahead-seeking statements in this press release discuss only as of the day of this push launch. EyeGate expressly disclaims any obligation or undertaking to launch publicly any updates or revisions to this sort of statements to replicate any improve in its expectations with regard thereto or any variations in the activities, circumstances or situation on which any these kinds of statement is dependent.

Trader Make contact with
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]